Voriconazole-associated myositis

Journal of Clinical Rheumatology

Volumn 15, Issue 7, 2009, Pages 350-353

  Shanmugam, Victoria K ^a   Matsumoto, Cal ^b   Pien, Edward ^a   Rosen, Jessica ^a   Kumar, Princy ^a   Whelton, Sean ^a   Steen, Virginia ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b International Center for Liver Diseases   (United States)

Author keywords

Myositis; Tacrolimus; Voriconazole

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; FLUDROCORTISONE; FRUCTOSE BISPHOSPHATE ALDOLASE; GABAPENTIN; TACROLIMUS; VORICONAZOLE;

ADULT; AFRICAN AMERICAN; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYOSITIS; OPPORTUNISTIC INFECTIONS; PYRIMIDINES; TRIAZOLES;

EID: 70350166143     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318188bea7     Document Type: Article

References (21)

1. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
2. Pearson MM, Rogers PD, Cleary JD, et al. Voriconazole: a new triazole antifungal agent. Ann Pharmacother. 2003;37:420-432.
3. Lees R, Lees A. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995;333:664-665.
4. Ferrari M, Bodini I, Lo Cascio V. Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis. Respiration. 2004;71:289-291.
5. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64:58-65.
6. Garty BZ, Kauli R, Livni E, et al. Myopathy associated with ketoconazole treatment. Am J Dis Child. 1991;145:970-971.
7. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology. 2004;43:603-608.
8. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-243.
9. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, doubledummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447-1454.
10. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415. (Pubitemid 34851833)
11. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35:509-513.
12. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis. 2002;35: 1273-1275.
13. Lutsar I, Hodges M, Tomaszewski K, et al. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087-1088.
14. Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56(suppl 1):2-9. (Pubitemid 37491727)
15. Venkataramanan R, Zang S, Gayowski T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother. 2002;46:3091-3093.
16. Kuypers DR, Claes K, Evenepoel P, et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. Transplantation. 2006;81:1750-1752.
17. Sadaba B, Campanero MA, Quetglas EG, et al. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc. 2004;36:3226 3228.
18. Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. Voriconazole Clin Ther. 2003;25:1321-1381.
19. Leather H, Boyette R, Tian L, et al. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:325-334.
20. Tintillier M, Kirch L, Goffin E, et al. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant. 2005; 20:664-665.
21. Orlandi V, Campieri C, Mosconi G, et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. Transplant Proc. 2004;36:708 710.